Writing in separate research notes, Leerink Swann's Dan Leonard and Goldman Sachs' Isaac Ro both cited the recent availability of new sample-preparation kits and higher-throughput instruments as evidence of the gene expression market "tipping in favor" of sequencing over microarrays.